SSKN vs. AKLI, MHUA, PAVM, GCTK, PYPD, TTOO, NEPH, PETV, NXGL, and IINN
Should you be buying STRATA Skin Sciences stock or one of its competitors? The main competitors of STRATA Skin Sciences include Akili (AKLI), Meihua International Medical Technologies (MHUA), PAVmed (PAVM), GlucoTrack (GCTK), PolyPid (PYPD), T2 Biosystems (TTOO), Nephros (NEPH), PetVivo (PETV), NEXGEL (NXGL), and Inspira Technologies Oxy B.H.N. (IINN). These companies are all part of the "surgical & medical instruments" industry.
STRATA Skin Sciences (NASDAQ:SSKN) and Akili (NASDAQ:AKLI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations, community ranking and risk.
STRATA Skin Sciences has higher revenue and earnings than Akili. STRATA Skin Sciences is trading at a lower price-to-earnings ratio than Akili, indicating that it is currently the more affordable of the two stocks.
32.4% of STRATA Skin Sciences shares are owned by institutional investors. Comparatively, 53.1% of Akili shares are owned by institutional investors. 40.4% of STRATA Skin Sciences shares are owned by insiders. Comparatively, 10.1% of Akili shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, STRATA Skin Sciences had 5 more articles in the media than Akili. MarketBeat recorded 7 mentions for STRATA Skin Sciences and 2 mentions for Akili. Akili's average media sentiment score of 0.99 beat STRATA Skin Sciences' score of 0.28 indicating that Akili is being referred to more favorably in the news media.
STRATA Skin Sciences received 217 more outperform votes than Akili when rated by MarketBeat users. However, 66.67% of users gave Akili an outperform vote while only 63.90% of users gave STRATA Skin Sciences an outperform vote.
STRATA Skin Sciences has a net margin of -32.47% compared to Akili's net margin of -3,545.47%. STRATA Skin Sciences' return on equity of -52.50% beat Akili's return on equity.
STRATA Skin Sciences presently has a consensus price target of $3.80, indicating a potential upside of 638.58%. Akili has a consensus price target of $4.00, indicating a potential upside of 1,532.65%. Given Akili's higher probable upside, analysts clearly believe Akili is more favorable than STRATA Skin Sciences.
STRATA Skin Sciences has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Comparatively, Akili has a beta of 1.99, meaning that its share price is 99% more volatile than the S&P 500.
Summary
STRATA Skin Sciences beats Akili on 9 of the 17 factors compared between the two stocks.
Get STRATA Skin Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SSKN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SSKN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
STRATA Skin Sciences Competitors List
Related Companies and Tools
